BioSpace News Archive

The Alzheimer Society of Canada in collaboration with Brain Canada Foundation, Canadian Institutes of Health Research – Institute of Aging, and Research Manitoba are investing $5,989,000 in 44 dementia researchers as part of its annual research competition.

Boehringer Ingelheim announced that the U.S. Food and Drug Administration has approved the newest innovation from the trusted NexGard® Brand of Products — NexGard® PLUS — a monthly beef-flavored soft chew that protects dogs from fleas, ticks, heartworm disease, roundworms and hookworms.

CEL-SCI Corporation announced the closing of its previously announced public offering of 2,500,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $5,000,000, before deducting underwriting discounts and offering expenses.

Guerbet, a global specialist in contrast agents and solutions for medical imaging, is reporting its revenue for the first half of 2023.

Palvella Therapeutics, Inc. today announced the planned pivotal Phase 3 study design of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), a topical mTOR inhibitor and the lead product candidate from the QTORIN™ platform, in Microcystic Lymphatic Malformations (Microcystic LMs).

Zynex, Inc. will hold a conference call on Thursday, July 27, 2023 at 4:15 PM Eastern Time to discuss its financial results for the second quarter, 2023 ended June 30, 2023.

PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules, is thrilled that – following pre-submission meetings held in Q1 of 2023 – it has received written guidance from the UK’s Medicines and Healthcare products Regulatory Agency’s.

EASEE®, the world’s first minimally invasive brain pacemaker, presented by Angela Liedler, CEO of Heidelberg-based Precisis, has been awarded top prize in this year’s ‘Shark Tank’ competition run by the Epilepsy Foundation.

Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases, announced its continued support of the Rady Children’s Institute for Genomic Medicine® (RCIGM) BeginNGS™ program (pronounced Beginnings) as it completes its inaugural year.

UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully completed the first-ever implant of the UroActive™ smart, automated artificial urinary sphincter (AUS) in a female patient.